Tilray Brands, Inc. (NASDAQ: TLRY) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -32.34 | Insider Own | 23.77% | Shs Outstand | 111.83M | Perf Week | -0.75% |
| Market Cap | 446.21M | Forward P/E | - | EPS next Y | -0.21 | Insider Trans | -0.07% | Shs Float | 134.29M | Perf Month | -17.39% |
| Enterprise Value | 618.63M | PEG | - | EPS next Q | -0.17 | Inst Own | - | Short Float | 13.45% | Perf Quarter | -15.64% |
| Income | -149.03M | P/S | 0.39 | EPS this Y | 98.46% | Inst Trans | - | Short Ratio | 4.45 | Perf Half Y | -40.09% |
| Sales | 1.16B | P/B | 0.28 | EPS next Y | 57.65% | ROA | -6.40% | Short Interest | 18.06M | Perf YTD | -55.81% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -7.95% | 52W High | 23.20 -82.80% | Perf Year | -66.47% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -2.98% | 52W Low | 3.67 8.72% | Perf 3Y | -86.43% |
| Dividend Est. | - | EV/EBITDA | 38.16 | Sales past 3/5Y | 2.69% 12.27% | Gross Margin | 27.57% | Volatility | 3.74% 4.31% | Perf 5Y | -96.78% |
| Dividend TTM | - | EV/Sales | 0.54 | EPS Y/Y TTM | 4.32% | Oper. Margin | -5.18% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.37 | Sales Y/Y TTM | 1.24% | Profit Margin | -12.90% | RSI (14) | 36.50 | Recom | 2.85 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.21 | EPS Q/Q | 57.00% | SMA20 | -8.82% | Beta | 1.90 | Target Price | 65.01 |
| Payout | 0.00% | Debt/Eq | 0.25 | Sales Q/Q | -8.44% | SMA50 | -9.12% | Rel Volume | 0.77 | Prev Close | 3.94 |
| Employees | 3,595 | LT Debt/Eq | 0.22 | Earnings | Oct 08 | SMA200 | -37.62% | Avg Volume | 4.01M | Price | 3.99 |
| IPO Date | Jul 19, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -3471.43% 14.38% | Net Debt/EBITDA | 10.63 | Volume | 3,091,751 | Change | 1.27% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-02-26 | Upgrade | Roth Capital | Neutral → Buy | |
| Jan-20-26 | Reiterated | Roth Capital | Neutral | $4.00 → $10 |
| Jan-09-26 | Reiterated | Industrial Alliance Securities | $10 | |
| Dec-19-25 | Reiterated | Bernstein | $1.00 → $10 | |
| Aug-25-25 | Reiterated | Jefferies | Buy | $1.50 → $2.00 |
| Jul-29-25 | Reiterated | Jefferies | Buy | $2.50 → $1.50 |
| Oct-11-24 | Reiterated | Piper Sandler | Neutral | $2.00 |
| Sep-11-24 | Reiterated | Jefferies | Buy | $2.50 |
| Jan-10-23 | Reiterated | Industrial Alliance Securities | $3.00 | |
| Sep-30-22 | Reiterated | Barclays | Underweight | $4.50 → $2.00 |
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 5/31/2026 | FY 2025 5/31/2025 | FY 2024 5/31/2024 | FY 2023 5/31/2023 | FY 2022 5/31/2022 | FY 2021 5/31/2021 | FY 2020 5/31/2020 | FY 2019 5/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,141 | 915 | 1,127 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 806 | 655 | 797 | — | — | — | — | — | — | |
| Gross Profit | 335 | 260 | 330 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 361 | 295 | 356 | — | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | — | — | — | — | — | — | |
| Other Operating Expense | 3,161 | 28 | 3,106 | — | — | — | — | — | — | |
| Operating Income | -3,187 | -63 | -3,132 | — | — | — | — | — | — | |
| Interest Expense | 41 | 30 | 57 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 10 | 5 | 30 | — | — | — | — | — | — | |
| Net Income Before Taxes | -3,218 | -88 | -3,159 | — | — | — | — | — | — | |
| Income Taxes | -166 | 17 | -166 | — | — | — | — | — | — | |
| Consolidated Net Income | -3,059 | -123 | -3,001 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -3,052 | -105 | -2,993 | — | — | — | — | — | — | |
| Net Income | -3,059 | -123 | -3,001 | — | — | — | — | — | — | |
| EPS (Recurring) | -32.34 | -1.09 | -33.80 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -32.34 | -1.09 | -33.80 | — | — | — | — | — | — | |
| EPS (Diluted) | -32.34 | -1.09 | -33.80 | — | — | — | — | — | — | |
| EBITDA | -2,975 | -39 | -2,919 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.34 | 0.67 | 0.34 | — | — | — | — | — | — | |
| Gross Margin | 29.36 | 28.42 | 29.28 | — | — | — | — | — | — | |
| Operating Margin | -279.32 | -6.89 | -277.91 | — | — | — | — | — | — | |
| Net Margin | -268.10 | -13.44 | -266.28 | — | — | — | — | — | — | |
| Shares Outstanding | 98 | 112 | 89 | — | — | — | — | — | — | |
| Market Capitalization | 391 | 617 | 379 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Merton Carl A | Chief Financial Officer | Aug 26 '26 | Option Exercise | 0.00 | 168,452 | 0 | 276,646 | Aug 27 |
| Gendel Mitchell | Global General Counsel | Aug 26 '26 | Option Exercise | 0.00 | 160,304 | 0 | 258,392 | Aug 27 |
| SIMON IRWIN D | President and CEO | Aug 26 '26 | Option Exercise | 0.00 | 1,212,168 | 0 | 1,734,920 | Aug 27 |
| FALTISCHEK DENISE M | Chief Strategy Officer | Aug 26 '26 | Option Exercise | 0.00 | 178,221 | 0 | 288,657 | Aug 27 |
| Gendel Mitchell | Global General Counsel | Aug 06 '26 | Buy | 4.43 | 2,500 | 11,075 | 124,883 | Aug 07 |
| Merton Carl A | Chief Financial Officer | Aug 04 '26 | Buy | 4.62 | 10,000 | 46,200 | 139,753 | Aug 04 |
| FALTISCHEK DENISE M | Chief Strategy Officer | Aug 03 '26 | Buy | 4.78 | 2,500 | 11,950 | 141,285 | Aug 04 |
| FALTISCHEK DENISE M | Chief Strategy Officer | Jul 30 '26 | Option Exercise | 0.00 | 26,120 | 0 | 152,629 | Jul 31 |
| SIMON IRWIN D | President and CEO | Jul 30 '26 | Option Exercise | 0.00 | 117,647 | 0 | 801,666 | Jul 31 |
| Merton Carl A | Chief Financial Officer | Jul 30 '26 | Option Exercise | 0.00 | 16,656 | 0 | 138,914 | Jul 31 |
| Gendel Mitchell | Global General Counsel | Jul 30 '26 | Option Exercise | 0.00 | 24,379 | 0 | 135,304 | Jul 31 |
| Gendel Mitchell | Global General Counsel | Jul 29 '26 | Option Exercise | 0.00 | 87,440 | 0 | 157,269 | Jul 31 |
| Merton Carl A | Chief Financial Officer | Jul 29 '26 | Option Exercise | 0.00 | 60,417 | 0 | 152,467 | Jul 31 |
| SIMON IRWIN D | President and CEO | Jul 29 '26 | Option Exercise | 0.00 | 428,448 | 0 | 911,097 | Jul 31 |
| FALTISCHEK DENISE M | Chief Strategy Officer | Jul 29 '26 | Option Exercise | 0.00 | 93,685 | 0 | 176,163 | Jul 31 |